ANCA相关肾小球肾炎的肾脏结局:诱导免疫抑制与病理分型的影响
这项回顾性多中心研究纳入304例活检证实的ANCA相关肾小球肾炎患者,按Berden病理分型分组,比较环磷酰胺(CYC)和利妥昔单抗(RTX)诱导治疗的肾脏结局。中位随访42个月,50%患者肾功能恢复,19.4%进展为肾衰竭。在新月体型中,RTX单药组eGFR恢复几率低于CYC组(OR 0.23,95%CI 0.05-0.98,P=0.047),肾衰竭风险边际升高(HR 3.42,95%CI 1.03-11.35,P=0.045);其他Berden分型无显著差异。
要点
- 新月体型ANCA肾炎中,RTX单药诱导的eGFR恢复几率低于CYC方案。
- 新月体型中RTX单药与肾衰竭风险升高边际相关,需谨慎选择。
- 其他Berden分型中不同诱导方案肾脏结局无显著差异。
核心结论
- 新月体型ANCA肾小球肾炎患者接受RTX单药诱导治疗,肾脏结局可能劣于以CYC为基础的方案。
研究设计与样本
- 回顾性多中心研究,纳入304例活检证实的ANCA肾小球肾炎患者,按Berden病理分型分组。
- 基线中位eGFR为20 ml/min per 1.73 m2(IQR 11-35),诱导方案为CYC 59%、RTX 17%、RTX-CYC 24%。
- 中位随访42个月(IQR 18-72),采用多变量回归模型分析肾脏结局预测因素。
主要发现
- 总体50%患者肾功能恢复,19.4%发生肾衰竭。
- 新月体型中,RTX组eGFR恢复几率低于CYC组(OR 0.23,95%CI 0.05-0.98,P=0.047)。
- 新月体型中,RTX组与RTX-CYC组eGFR恢复比较无显著差异(OR 0.20,95%CI 0.03-1.19,P=0.077)。
- 新月体型中,RTX单药与CYC相比肾衰竭风险边际升高(HR 3.42,95%CI 1.03-11.35,P=0.045)。
- 新月体型中,RTX单药与RTX-CYC相比肾衰竭风险无显著差异(HR 5.33,95%CI 0.91-31.18,P=0.063);其他Berden分型无显著差异。
关键数值与推荐
- eGFR恢复定义为6个月时eGFR升高≥15 ml/min per 1.73 m2或脱离肾脏替代治疗(KRT)。
- 肾衰竭定义为持续eGFR < 15 ml/min per 1.73 m2或长期KRT。
临床怎么用
- 对新月体型ANCA肾小球肾炎患者,选择诱导方案时应考虑RTX单药可能肾脏预后较差。
- 需结合病理分型个体化选择CYC、RTX或联合方案,并进一步研究验证。
局限性
- 回顾性研究设计,可能存在选择偏倚和混杂因素。
- 部分比较的置信区间较宽且P值接近0.05,结果需谨慎解读。
- 样本量有限,新月体型亚组分析效能不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Cyclophosphamide (CYC) and rituximab (RTX), alone or combined, are the mainstays of induction therapy in antineutrophil cytoplasmic autoantibody (ANCA)-glomerulonephritis. It is unknown whether the response to induction is differentially affected by kidney histopathology. METHODS: This is a retrospective, multicenter study including patients with biopsy-proven ANCA-glomerulonephritis. Cases were grouped according to the Berden nephropathology classification. Estimated glomerular filtration rate (eGFR) recovery at 6 months was defined as eGFR increase ≥ 15 ml/min per 1.73 m2 or discontinuation of kidney replacement therapy (KRT); kidney failure was defined as sustained eGFR < 15 ml/min per 1.73 m2 or long-term KRT. Multivariable regression models were used to explore independent predictors of kidney outcomes across Berden classes. RESULTS: The cohort included 304 patients; median baseline eGFR was 20 ml/min per 1.73 m2 (interquartile range [IQR]: 11-35). Induction immunosuppression was with CYC in 59%, with RTX in 17%, and with RTX-CYC in 24%. Overall, 50% recovered kidney function and 19.4% had kidney failure over a median follow-up of 42 months (IQR: 18-72). In the crescentic class, the RTX group had lower chances of eGFR recovery than CYC (odds ratio [OR]: 0.23, 95% confidence interval [CI]: 0.05-0.98, P = 0.047); the trend was similar in comparison with RTX-CYC (OR: 0.20, 95% CI: 0.03-1.19, P = 0.077). In the crescentic class, RTX monotherapy was marginally associated with increased risk of kidney failure, compared with both CYC (hazard ratio [HR]: 3.42, 95% CI: 1.03-11.35, P = 0.045) and RTX-CYC (HR: 5.33, 95% CI: 0.91-31.18, P = 0.063). No significant differences were observed in the other Berden classes. CONCLUSION: Patients with crescentic class ANCA-glomerulonephritis receiving RTX monotherapy may have worse kidney outcomes than those treated with CYC-based regimens. Further studies are needed to validate these results and better understand how to personalize treatment.
引用
- Uzzo M, Mescia F, Scott J, et al. Kidney Outcomes in ANCA-Glomerulonephritis According to Induction Immunosuppression and Histopathology. Kidney Int Rep. 2026. PMID: 41716736. doi:10.1016/j.ekir.2026.103776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。